Setup. Zymeworks (ZYME) pivoted from drug development to royalty aggregation, anchored by zanidatamab — a HER2 bispecific antibody licensed to Jazz Pharmaceuticals as Ziihera. The sBLA for first-line HER2+ gastric/GEJ adenocarcinoma has a PDUFA date of August 25, 2026. Approval triggers $250M from Jazz to ZYME plus $50M from BeOne contingent on China NMPA. The catalyst owner trades at a 36% discount to consensus targets while the downstream commercial partner (JAZZ) is up 15.6% in the past month into the same event.

What the filing says. Q1 2026 earnings pinned PDUFA to August 25, 103 days from the call. The sBLA is under RTOR (real-time oncology review) with BTD + Fast Track + Priority Review. HERIZON-GEA-01 Phase 3: 35% PFS risk reduction, 26.4-month OS, 20.7-month duration of response vs 8.3 months control. Jazz Q1 Ziihera sales $13M, accelerating from a $6M→$8M→$10M→$13M trajectory in the existing 2L+ BTC indication. Leadership reconstituted: CFO Kristin Stafford (royalty aggregation profile), GC Paul Schneider from Pfizer. Cash $403.8M; $95.8M buyback deployed YTD; runway guided beyond 2028. A second HERIZON-GEA OS interim is expected mid-2026, before PDUFA — management was deliberately vague about regulatory strategy, signaling active FDA negotiation. CEO confirmed "active conversations" on ZW191 partnership and an external M&A acquisition pipeline.

The ZW191 AACR 2026 data (68% ORR in platinum-resistant ovarian, activity regardless of FRα expression) looks differentiated on raw numbers. Cross-corpus checking revealed the "FRα-agnostic" positioning is the explicit, repeated differentiation of two more advanced competitors: Genmab Rina-S (Phase 3 RAINFOL-02 enrollment complete Q1 2026, 2027 launch guided) and Lilly sofetibart mepetecan (BTD January 2026, two Phase 3 trials). ZW191 is Phase 1. Third-mover. A pan-RAS ADC platform (three preclinical candidates) was disclosed at AACR; cross-search of 10,607 transcripts found no public competitor with the format. Preclinical, 3-4 years from clinical PoC.

What the market thinks. Sell-side: 14 analysts, 100% bullish, mean target $38.54. Options: P/C OI ratio 8.34, inverted call skew (OTM calls cheaper than ATM), IV at 84th percentile. Stock -7.6% week, RSI 34. JAZZ +15.6% over the same period. Triangulating across options skew, price vs consensus, and price vs probability-weighted fair value: market-implied P(approval) ≈ 50-60%.

The gap. Our P = 72%. Edge of 12-22 percentage points. Three reasons it exists.

First, RTOR is opaque — FDA has been engaged with this data for months, but there's no public progress signal. Second, Q1 2026 EPS missed (-$0.59 vs -$0.10) on a base-effect distortion (Q1 2025 had $27.1M non-recurring milestones vs $2.4M in Q1 2026); operating expenses were actually down. Generalist forced selling on the optical miss. Third, the cross-ticker read-through hasn't been synthesized: JAZZ buying the approval, ZYME selling it. The market is buying the consequence and selling the cause.

Risks, ranked.

1. CRL (13% probability). Floor at cash + Ziihera 2L residual ≈$15-18. Drawdown -25 to -45%. Refile path 12-18 months; resets but not terminal.
2. PDUFA delay 30-90 days (15%). Major Amendment classification adds 3 months. Thesis intact, timing shifted.
3. ZW191 third-mover lockout. Partnership economics capped $200-500M upfront, not $1B+. Already priced in; further compression possible if ESMO Gynae data underwhelms.
4. Sector beta drag. Trailing idio variance only 52.7% — below 75% target. 47% of returns come from XBI/market/size. Forward idio rises as PDUFA approaches but pair with XBI hedge to isolate alpha.
5. Royalty constraints. RPRX has a veto on Jazz-relationship changes and further royalty monetization. Reduced strategic flexibility on the most valuable asset.

Catalysts.

• ESMO Gynae 2026 (Copenhagen, June 2026) — ZW191 dose optimization data
• HERIZON-GEA second OS interim (mid-2026, May-July window) — Jazz 8-K Item 7.01 expected
• Jazz Q2 2026 earnings (late July / early August) — pre-PDUFA launch readiness commentary
• August 25, 2026 — PDUFA decision
• Q3 2026 — first Jazz commercial print on 1L launch trajectory
• Through Q1 2027 — RPRX first royalty receipt from ZYME interest

What would change our mind.

• Pre-PDUFA deficiency letter or Major Amendment notification → P(approval) toward 0.40
• Form 483 inspection findings at Jazz/CMO manufacturing site
• FDA AdCom announcement (uncommon for RTOR; signals approvability concerns)
• HERIZON-GEA OS interim mixed or immature → P drops to ≈0.65
• ZW191 ESMO Gynae data showing DOR < 6 months or material safety concern
• Jazz Q2 Ziihera sales below $12M (signals demand exhaustion pre-1L launch)
• 2+ insider Form 4 P-code purchases in pre-PDUFA window → push our P to 0.78

LR signal: 1.5. Bullish — market underweighting. The probability gap is specific and quantifiable; the cross-ticker mispricing is named; the catalyst is non-reflexive (FDA decision independent of price). Resisting LR > 1.8: the bull thesis depends on a single binary that 14 analysts already cover, the ZW191 third-mover trim cuts the optionality stack we'd ordinarily lean on, and trailing idio variance below 75% means part of the alpha is sector-correlated.

Evidence